What is WAVE Life Sciences Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. WAVE Life Sciences's interest expense for the
three
months ended in Dec. 2024 was $ 0.0 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $0.0 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. WAVE Life Sciences's Operating Income for the
three
months ended in Dec. 2024 was $ 23.0 Mil. WAVE Life Sciences's Interest Expense for the
three
months ended in Dec. 2024 was $ 0.0 Mil.
GuruFocus does not calculate WAVE Life Sciences's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
WAVE Life Sciences Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAVE Life Sciences (NAS:WVE) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
WAVE Life Sciences's Interest Expense for the
three
months ended in Dec. 2024 was $0.0 Mil. Its
Operating Income
for the
three
months ended in Dec. 2024 was $23.0 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2024 was $17.8 Mil.
WAVE Life Sciences's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as
| GuruFocus does not calculate WAVE Life Sciences's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. WAVE Life Sciences Ltd has enough cash to cover all of its debt. Its financial situation is stable.
WAVE Life Sciences Business Description
Traded in Other Exchanges
Address
7 Straits View No. 12-00, Marina One East Tower, Singapore, SGP, 018936
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Executives
| Paul Bolno |
director, officer: See Remarks |
C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138 |
| Chris Francis |
officer: See Remarks |
C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138 |
| Plc Glaxosmithkline |
10 percent owner |
980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS |
| Kyle Moran |
officer: See Remarks |
C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138 |
| Ra Capital Healthcare Fund Lp |
10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Chandra Vargeese |
officer: See Remarks |
C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE, CAMBRIDGE MA 02138 |
| Michael A. Panzara |
officer: Franchise Lead, Neurology |
733 CONCORD AVENUE, CAMBRIDGE MA 02138 |
| Ra Capital Management, L.p. |
director, 10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Rajeev M. Shah |
10 percent owner |
200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
| Aik Na Tan |
director |
C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138 |
| David G Gaiero |
officer: Interim CFO |
733 CONCORD AVENUE, C/O WAVE LIFE SCIENCES USA, INC., CAMBRIDGE MA 02138 |
| Gregory L. Verdine |
director |
C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE, CAMBRIDGE MA 02138 |
| Heidi L Wagner |
director |
C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138 |
| Amy Pott |
director |
C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138 |
| Mark Corrigan |
director |
|
WAVE Life Sciences Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
WVE has been successfully added to your 